Skip to main content
GRAIL, Inc. logo

GRAIL, Inc. — Investor Relations & Filings

Ticker · GRAL ISIN · US3847471014 LEI · 2549009XSNESW3VE8024 US Professional, scientific and technical activities
Filings indexed 198 across all filing types
Latest filing 2026-04-28 Proxy Solicitation & In…
Country US United States of America
Listing US GRAL

About GRAIL, Inc.

https://grail.com/

GRAIL, Inc. is a healthcare company dedicated to detecting cancer early. Its mission is to reduce the global burden of cancer through early diagnosis when treatment may be more effective. The company's flagship product is the Galleri® test, a blood-based multi-cancer early detection (MCED) test. The Galleri test is designed to screen for a signal shared by multiple types of cancer, including many that lack recommended screening methods, often before symptoms appear. GRAIL develops its technology by leveraging next-generation sequencing (NGS), machine learning, and data from population-scale clinical studies. The company's focus is on identifying deadly cancers in their initial stages to improve patient outcomes.

Recent filings

Filing Released Lang Actions
DEF 14A - GRAIL, Inc. (0001699031) (Filer)
Proxy Solicitation & Information Statement
2026-04-28 English
SCHEDULE 13G/A - GRAIL, Inc. (0001699031) (Subject)
Major Shareholding Notification
2026-03-27 English
4 - GRAIL, INC. (0001699031) (Filer)
Director's Dealing
2026-03-04 English
4 - GRAIL, INC. (0001699031) (Filer)
Director's Dealing
2026-03-04 English
4 - GRAIL, INC. (0001699031) (Filer)
Director's Dealing
2026-03-04 English
8-K - GRAIL, INC. (0001699031) (Filer)
Regulatory Filings
2026-02-19 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.